Compass Pathways submits COMP360 psilocybin application to FDA for treatment-resistant depression
Summary
Compass Pathways has submitted a new drug application to the FDA for COMP360 psilocybin for treatment-resistant depression. The company says its submission includes data from more than 1,000 participants, which it describes as the largest cohort in a psychedelic drug development program. The FDA is also reviewing applications for MDMA for PTSD and psilocybin for major depressive disorder. Compass is preparing its commercialisation and sales efforts and is targeting a launch in the first half of 2027. The application has been submitted, but an FDA approval decision has not yet been reported.